Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Fundus albipunctatus is a rare, autosomal recessive form of congenital stationary night blindness characterized by delayed dark adaptation and widespread white‐yellow flecks in the midperipheral retina. The disorder is caused by biallelic loss‐of‐function variants in RDH5, which encodes the 11-cis retinol dehydrogenase enzyme responsible for the conversion of 11-cis retinol to 11-cis retinal in the retinal pigment epithelium.
Extensive genetic and functional data establish a definitive gene–disease relationship between RDH5 and fundus albipunctatus. Over 100 unrelated probands with biallelic RDH5 variants have been reported across multiple populations, including 25 patients from 22 Japanese pedigrees (PMID:32232344), 20 Israeli patients (PMID:22815624), and founder analyses in six Japanese patients (PMID:10845614). Segregation consistent with autosomal recessive inheritance has been documented in at least 19 additional affected relatives (PMID:10369264). Functional concordance is provided by biochemical assays demonstrating loss of enzyme activity in vitro and dominant‐negative effects of certain mutants (PMID:11675386).
ClinGen category: Definitive
Inheritance is autosomal recessive, with pathogenic alleles identified in homozygous or compound heterozygous states. The variant spectrum includes missense (e.g., c.839G>A (p.Arg280His)), nonsense, frameshift, splice‐site, and in‐frame indels. A recurrent founder mutation, 1085delC/insGAAG, accounts for multiple Japanese cases (PMID:10845614). Additional variants reported include c.218C>T (p.Ser73Phe) and c.712G>T (p.Gly238Trp) in unrelated families (PMID:10369264; PMID:10617778).
ClinGen genetic evidence: Strong – >100 distinct variants across >50 families, robust segregation data
In vitro expression of 11-cis retinol dehydrogenase mutants reveals markedly reduced protein stability, mislocalization, and loss of catalytic activity. Cross‐linking and modeling confirm a dimeric structure, and co-expression studies show trans-dominant-negative effects on residual wild-type enzyme, explaining recessive inheritance (PMID:11675386). Alternative oxidizing pathways in RPE partially compensate but cannot restore normal kinetics of dark adaptation (PMID:11153648).
ClinGen functional evidence: Moderate – concordant biochemical and cell-biological assays
Patients uniformly present with nyctalopia (HP:0000662) and fundus albipunctatus (HP:0030642) manifested by delayed rod and cone recovery. Macular involvement and progressive cone dysfunction occur in older individuals (PMID:32232344), and rare cases develop cone dystrophy or sectoral retinitis pigmentosa.
Biallelic RDH5 variants cause a definitive, autosomal recessive fundus albipunctatus phenotype, combining clinical stationarity of night blindness with characteristic fundus flecks and delayed dark adaptation. Genetic testing of RDH5 informs diagnosis, carrier screening, and potential future therapies aimed at visual cycle modulation.
Take-home: RDH5 sequencing should be standard in congenital night‐blindness workups, as pathogenic variants reliably predict fundus albipunctatus and guide management.
Gene–Disease AssociationDefinitive
Genetic EvidenceStrong
Functional EvidenceModerateBiochemical and cell-biological assays demonstrate loss of 11-cis RDH activity and dominant-negative effects (PMID:11675386) |